US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Frontier Medicines
Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026
Today 3:30 EDT
From
Frontier Medicines
Via
Business Wire
Frontier Medicines to Present First Clinical Data for FMC-376, an Equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026
October 19, 2026
From
Frontier Medicines
Via
Business Wire
Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines
January 05, 2026
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets
October 22, 2025
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Announces Third Precision Oncology Development Candidate
October 14, 2025
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation
October 03, 2025
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025
April 28, 2025
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines to Participate in Two Upcoming March Investor Conferences
February 27, 2025
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
January 09, 2025
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor
July 23, 2024
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension
June 25, 2024
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting
April 09, 2024
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024
March 06, 2024
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines to Participate in Upcoming Investor Conferences
February 27, 2024
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
February 22, 2024
From
Frontier Medicines
Via
GlobeNewswire
Tickers
GLPG
Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer
May 08, 2023
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting
April 16, 2023
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting
March 14, 2023
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development
February 28, 2023
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies
January 05, 2023
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie
January 05, 2023
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines Announces Appointment of Accomplished Finance and Operations Executive, Setareh “SiSi” Pouraghabagher, to Board of Directors
November 08, 2022
From
Frontier Medicines
Via
GlobeNewswire
Frontier Medicines to Present at Credit Suisse 31st Annual Healthcare Conference
November 01, 2022
From
Frontier Medicines
Via
GlobeNewswire
